瑞戈非尼治疗7例肝细胞癌的早期经验。
Early experience of seven hepatocellular carcinoma cases treated with regorafenib.
作者信息
Uchikawa Shinsuke, Kawaoka Tomokazu, Aikata Hiroshi, Kodama Kenichiro, Inagaki Yuki, Hatooka Masahiro, Morio Kei, Nakahara Takashi, Murakami Eisuke, Hiramatsu Akira, Tsuge Masataka, Imamura Michio, Kawakami Yoshiiku, Chayama Kazuaki
机构信息
Department of Gastroenterology and Metabolism, Applied Life Sciences Institute of Biomedical & Health Sciences Hiroshima University Hiroshima Japan.
出版信息
Clin Case Rep. 2018 Oct 11;6(11):2217-2223. doi: 10.1002/ccr3.1791. eCollection 2018 Nov.
Regorafenib became second-line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.
瑞戈非尼成为索拉非尼难治性患者的二线治疗药物。在我们的研究中，两名患者因不良反应无法继续使用瑞戈非尼。建议应遵守瑞戈非尼的适当使用标准，并尽早处理不良反应。
Zotero 插件